Over the past several years, we have evaluated tamibarotene in multiple clinical trials, which have consistently demonstrated activity with potential for meaningful benefit to patients with hematologic malignancies. Most notable clinical data can be found below.
December 6, 2023 | Initial Randomized Data from SELECT-AML-1 Study, a Phase 2 study of Tamibrotene in Combination with Venetoclax and Azacitidine in RARA-positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy - prespecified analysis of 23 patients
Data Slide Deck
Webcast Replay of Conference Call
December, 2017-2020, ASH | A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
2020 ASH Oral Presentation Slide Deck - Newly Diagnosed AML
2020 ASH Oral Presentation Slide Deck - R/R AML
2017 ASH Poster Presentation
Publication in Blood Advances
Publication in Leukemia & Lymphoma
